Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products

Joseph V. Pergolizzi; Christopher G. Gharibo; Jeffrey A. Gudin; Srinivas R. Nalamachu

doi:10.1111/papr.12040

Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products

Joseph V. Pergolizzi, Christopher G. Gharibo, Jeffrey A. Gudin, Srinivas R. Nalamachu

School of Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	259-263
Number of pages	5
Journal	Pain Practice
Volume	13
Issue number	4
DOIs	https://doi.org/10.1111/papr.12040
State	Published - Apr 2013

ASJC Scopus subject areas

Anesthesiology and Pain Medicine

Access to Document

10.1111/papr.12040

Cite this

@article{45f84497e421476a81b8b45862ff0d18,

title = "Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products",

author = "Pergolizzi, {Joseph V.} and Gharibo, {Christopher G.} and Gudin, {Jeffrey A.} and Nalamachu, {Srinivas R.}",

year = "2013",

month = apr,

doi = "10.1111/papr.12040",

language = "English (US)",

volume = "13",

pages = "259--263",

journal = "Pain Practice",

issn = "1530-7085",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products

AU - Pergolizzi, Joseph V.

AU - Gharibo, Christopher G.

AU - Gudin, Jeffrey A.

AU - Nalamachu, Srinivas R.

PY - 2013/4

Y1 - 2013/4

UR - http://www.scopus.com/inward/record.url?scp=84875964538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875964538&partnerID=8YFLogxK

U2 - 10.1111/papr.12040

DO - 10.1111/papr.12040

M3 - Article

C2 - 23464790

AN - SCOPUS:84875964538

SN - 1530-7085

VL - 13

SP - 259

EP - 263

JO - Pain Practice

JF - Pain Practice

IS - 4

ER -

Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this